rs150418024
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 0P and 8B. BP4_StrongBS2
The NM_001371596.2(MFSD8):c.1006G>C(p.Glu336Gln) variant causes a missense change. The variant allele was found at a frequency of 0.00251 in 1,613,718 control chromosomes in the GnomAD database, including 13 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_001371596.2 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MFSD8 | NM_001371596.2 | c.1006G>C | p.Glu336Gln | missense_variant | Exon 10 of 12 | ENST00000641686.2 | NP_001358525.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00227 AC: 345AN: 152134Hom.: 1 Cov.: 32
GnomAD3 exomes AF: 0.00243 AC: 610AN: 250906Hom.: 3 AF XY: 0.00236 AC XY: 320AN XY: 135640
GnomAD4 exome AF: 0.00254 AC: 3713AN: 1461466Hom.: 12 Cov.: 31 AF XY: 0.00242 AC XY: 1762AN XY: 727046
GnomAD4 genome AF: 0.00227 AC: 345AN: 152252Hom.: 1 Cov.: 32 AF XY: 0.00253 AC XY: 188AN XY: 74450
ClinVar
Submissions by phenotype
not provided Uncertain:2Benign:2
- -
- -
Identified in multiple unrelated individuals with nonsyndromic macular dystrophy or cone dystrophy who also had a pathogenic MFSD8 variant, suggesting E336Q may cause hypomorphic macular dystrophy when in trans with a pathogenic variant (Roosing et al., 2015; Khan et al., 2017; Haer-Wigman et al., 2017); Published functional studies suggest a damaging effect on CLN7 chloride channel characteristics (Wang et al., 2021); This variant is associated with the following publications: (PMID: 27527004, 26681805, 25227500, 27654426, 30215852, 28559085, 28224992, 28586915, 34426522, 30382371, 33546218, 34910516) -
MFSD8: BS1 -
Macular dystrophy with central cone involvement Pathogenic:2
- -
- -
Neuronal ceroid lipofuscinosis 7 Uncertain:1Benign:1
This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. -
- -
Optic atrophy Pathogenic:1
- -
Retinal dystrophy Pathogenic:1
- -
Neuronal ceroid lipofuscinosis 7;C4015371:Macular dystrophy with central cone involvement Uncertain:1
- -
Inborn genetic diseases Uncertain:1
The p.E336Q variant (also known as c.1006G>C), located in coding exon 10 of the MFSD8 gene, results from a G to C substitution at nucleotide position 1006. The glutamic acid at codon 336 is replaced by glutamine, an amino acid with highly similar properties.This alteration has been detected in individuals with maculopathies and cone disorders and is characterized as a hypomorphic variant that only causes cone dysfunction when it is present in combination with a severe MFSD8 variant (Roosing S, Ophthalmology 2015 Jan; 122(1):170-9; Khan KN et al. Invest. Ophthalmol. Vis. Sci., 2017 Jun;58:2906-2914; Haer-Wigman L et al. Eur. J. Hum. Genet., 2017 05;25:591-599). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
not specified Benign:1
Variant summary: MFSD8 c.1006G>C (p.Glu336Gln) results in a conservative amino acid change located in the Major facilitator superfamily domain (IPR020846) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0025 in 282298 control chromosomes (gnomAD), predominantly at a frequency of 0.0031 within the Non-Finnish European subpopulation in the gnomAD database, including 2 homozygotes. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 3 fold of the estimated maximal expected allele frequency for a pathogenic variant in MFSD8 causing Neuronal Ceroid-Lipofuscinosis (Batten Disease) phenotype (0.00094), strongly suggesting that the variant is a benign polymorphism found primarily in populations of Non-Finnish European origin. c.1006G>C has been reported in the literature as a biallelic genotype in individuals affected with macular dystrophy (e.g. Roosing_2015). These individuals show no signs of neurological involvement, and patients were diagnosed with macular dystrophy at an advanced age compared to those with Neuronal ceroid lipofuscinosis 7 (27-57 years at age of diagnosis as compared to 2-7 years of age for NCL). Therefore, these reports do not provide unequivocal conclusions about association of the variant with Neuronal Ceroid-Lipofuscinosis (Batten Disease). Nine ClinVar submitters have assessed the variant since 2014: three classified the variant as uncertain significance, two as likely pathogenic, one as pathogenic, and three as benign. Based on the evidence outlined above, the variant was classified as likely benign. -
Late-infantile neuronal ceroid lipofuscinosis Benign:1
- -
MFSD8-related disorder Benign:1
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at